Characteristics of case-control studies included in TGFBR1 IVS7+24G>A polymorphism and cancer risk.

<p>Characteristics of case-control studies included in TGFBR1 IVS7+24G>A polymorphism and cancer risk.</p

Forest plot (random effects model) describing the association of the IVS7+24G>A polymorphism with risk of cancer.

<p>The IVS7+24G>A polymorphism was associated with increased cancer risk in additive model.</p

Pooled analysis of association of TGFBR1 TGFBR1*6A (rs1466445) and cancer risk.

<p><i>P</i>_h: test for heterogeneity, OR: odds ratio, CI: confidence interval, N: number of data sets.</p><p><i>I²</i> : the percentage of total variation across studies that is a result of heterogeneity rather than chance.</p>a<p>Random-effects model was used; otherwise, fixed-effects model was used.</p

Funnel plot analysis (recessive model of TGFBR1*6A polymorphism) to detect publication bias.

<p>Each point represents an individual study for the indicated association. LogOR, natural logarithm of OR. Perpendicular line, mean effect size.</p

Characteristics of case-control studies included in TGFBR1 TGFBR1*6A polymorphism and cancer risk.

a<p>The combination of Leukemia, lymphoma and MM (multiple myeloma).</p>b<p>This study was excluded from the combined allelic effect and recessive model because of insufficient data on the frequencies of 9A/6A and 6A/6A genotype.</p><p>NS: not stated, ALL: acute lymphocytic leukemia.</p

Influence analysis of the summary odds ratio coefficients on the association between IVS7+24G>A polymorphism and cancer risk in recessive model.

<p>Results were computed by omitting each study (left column) in turn. Bars, 95% confidence interval.</p

Forest plot (random effects model) describing the association of the TGFBR1*6A polymorphism with risk of cancer.

<p>The TGFBR1*6A polymorphism was associated with increased risk of cancer in additive model. Each study is shown by the point estimate of the OR (the size of the square is proportional to the weight of each study) and 95% CI for the OR (extending lines).</p

Pooled analysis of association of IVS7+24G>A (rs334354) and cancer risk.

<p><i>P</i>_h: test for heterogeneity, OR: odds ratio, CI: confidence interval, N: number of data sets.</p><p><i>I²</i> : the percentage of total variation across studies that is a result of heterogeneity rather than chance.</p

Flow diagram of study identification.

<p>Flow diagram of study identification.</p

Is CD133 Expression a Prognostic Biomarker of Non-Small-Cell Lung Cancer? A Systematic Review and Meta-Analysis

<div><p>Background</p><p>The clinical and prognostic significance of CD133 in non-small-cell lung cancer (NSCLC) remains controversial. To clarify a precise determinant of the clinical significance of CD133, we conducted a systematic review and meta-analysis to evaluate the association of CD133 with prognosis and clinicopathological features of NSCLC patients.</p><p>Methods</p><p>The electronic and manual searches were performed through the database of Pubmed, Medline, Web of Science, Scopus, and Chinese CNKI (from January 1, 1982 to January 1, 2014) for titles and abstracts by using the following keywords: “CD133”, “ac133” or “Prominin-1”, and “lung cancer” to identify the studies eligible for our analysis. Meta-analysis was performed by using Review Manager 5.0 and the outcomes included the overall survival and various clinicopathological features.</p><p>Results</p><p>A total of 23 studies were finally included, and our results showed that CD133 level was significantly correlated with the overall survival (OR = 2.25, 95% CI: 1.24–4.07, <i>P</i> = 0.008) of NSCLC patients but not with the disease free survival (OR = 1.33, 95% CI = 0.77–2.30, <i>P</i> = 0.31). With respect to clinicopathological features, CD133 level was positively correlated with lymph node metastasis (OR = 1.99, 95%CI = 1.06–3.74, <i>P</i> = 0.03), but not correlated with the histological classification (OR = 1.00, 95%CI = 0.81–1.23, <i>P</i> = 0.99(ac), OR = 0.87, 95%CI = 0.61–1.24, <i>P</i> = 0.45(sc)), or differentiation (OR = 0.94, 95%CI 0.53–1.68, Z = 0.20, <i>P</i> = 0.84 random-effect) of NSCLC patients.</p><p>Conclusion</p><p>High level of CD133 expression trends to correlate with a worse prognosis and a higher rate of lymph node metastasis in NSCLC patients, revealing CD133 as a potential pathological prognostic marker for NSCLC patients.</p></div